Regulatory Affairs
NAFDAC DG Urges Businesses to Prioritise Regulatory Compliance as Competitiveness Strategy
NAFDAC Director-General Prof. Mojisola Adeyeye has urged Nigerian businesses to prioritise regulatory compliance to strengthen consumer confidence, protect public health and improve access to local and international markets. She also received an award from NACCIMA.
The Director-General of the National Agency for Food and Drug Administration and Control (NAFDAC), Prof. Mojisola Adeyeye, has urged Nigerian businesses to embrace regulatory compliance as a strategic investment in public health, consumer confidence and competitiveness in local and international markets.
Adeyeye made the call on Wednesday, 4 November 2026, while delivering the keynote address at the Nigerian Association of Chambers of Commerce, Industry, Mines and Agriculture (NACCIMA) Breakfast Roundtable held at Providence Hotel, Lagos.
Speaking on the theme, “Strengthening Regulatory Compliance for Competitive Nigerian Businesses: Enhancing Food and Drug Safety for Local and International Markets,” she emphasised that compliance should not be viewed solely as a legal obligation but as an essential component of business sustainability and market development.
According to her, businesses that prioritise regulatory standards are better positioned to ensure the safety, quality and efficacy of their products while building consumer trust and strengthening their prospects in international markets.
Regulatory Compliance and Business Development
Adeyeye highlighted NAFDAC's regulatory processes, including product registration, licensing, inspections, laboratory testing and post-market surveillance, as important mechanisms for ensuring that regulated products meet established safety and quality requirements.
She stressed the need for businesses to implement Good Manufacturing Practices (GMP), establish robust quality management systems and strengthen product traceability.
The NAFDAC Director-General also identified technology adoption and continuous staff training as important components of effective regulatory compliance.
For pharmaceutical manufacturers and other businesses operating within the regulated healthcare sector, these measures are essential to maintaining product quality, supporting regulatory oversight and ensuring that medicines and other regulated products meet applicable standards.
She further called for stronger collaboration among regulatory authorities, industry stakeholders, academia and consumers to improve compliance and enhance the acceptance of Nigerian products in global markets.
NACCIMA Recognises NAFDAC Director-General
At the event, Adeyeye received an Award of Excellent Performance from NACCIMA in recognition of her performance, dedication and contributions to public health protection and industry development.
The recognition came during the roundtable, which focused on strengthening regulatory compliance as a means of improving business competitiveness and promoting food and drug safety.
The discussions also highlighted the relationship between regulatory standards, consumer confidence and the ability of Nigerian businesses to compete in local and international markets.
Implications for the Pharmaceutical Industry
NAFDAC's emphasis on regulatory compliance has particular relevance to pharmaceutical manufacturers, importers, distributors and other stakeholders in Nigeria's medicines supply chain.
Effective compliance supports the production and distribution of quality-assured medicines, strengthens traceability and helps regulatory authorities identify and address products that fail to meet established standards.
For businesses seeking access to international markets, adherence to applicable regulatory requirements is also an important consideration in demonstrating product quality and meeting market-specific expectations.
The call reinforces the importance of integrating regulatory requirements into business operations rather than treating compliance as a responsibility addressed only during inspections or product registration.
For the pharmaceutical sector, sustained collaboration between regulators and industry will remain important in strengthening quality assurance, protecting consumers and supporting the development of a more competitive medicines market.
Pharmacy Times Nigeria will continue to report on regulatory developments affecting pharmaceutical businesses, medicines safety and the healthcare industry.
More like this
NAFDAC Debunks Claims That Camosunate Has Been Banned in Nigeria
21 Nov 2026
NAFDAC Destroys ₦100 Billion Worth of Falsified, Expired and Banned Products in Ogun State
21 Nov 2026
PCN Seals 261 Medicine Outlets Following FCT Enforcement Exercise
20 Nov 2026